All In Biotech

Free tool

FAERS Monitor: Susvimo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761197 or its brand name (Susvimo, Ranibizumab). Reports on generic versions are filed under their own applications.

Reports

5,319

Serious

5,059

95% of reports

Hospitalization

1,483

Death reported

751

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • visual acuity reduced545
  • death380
  • off label use295
  • retinal haemorrhage270
  • cerebrovascular accident265
  • vitreous haemorrhage214
  • drug ineffective209
  • endophthalmitis207
  • myocardial infarction181
  • visual impairment172
  • cataract164
  • retinal pigment epithelial tear149
  • fall148
  • no adverse event131
  • blindness126

Reports by year received

View as table
YearReports
20063
200753
200867
2009142
2010241
2011240
2012565
2013996
2014442
2015334
2016234
2017193
2018208
2019208
2020129
2021162
2022253
2023277
2024210
2025219
2026143

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,840 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
retinal pigment epithelial tearSignal1491081.9904.4125,516
vitreous haemorrhageSignal214331.8289.464,829
retinal haemorrhageSignal270155.8138.339,808
endophthalmitisSignal207141.3123.327,712
visual acuity reducedSignal54566.060.934,283
blindnessSignal12612.310.31,291
cataractSignal16410.99.41,468
cerebrovascular accidentSignal2656.25.51,156
visual impairmentSignal1725.54.7631
myocardial infarctionSignal1814.13.6425
no adverse eventSignal1312.92.4158
fall1481.81.548
death3801.71.6125
off label use2951.31.225
drug ineffective2090.60.549

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.